In the recent years pharmacological hormonal therapy has been introduced aiming to stimulate intestinal adaptation after intestinal resections. There are studies involving growth hormone, glutamine, and glucagon-like peptide 2 growth hormone (GLP-2).
The U.S. Food and Drug Administration (FDA) has approved both growth hormone and glutamine as drugs to be used in the management of SBS. Most recently in 2012, teduglutide (Gattex®), a recombinant analog of human glucagon-like peptide 2, was FDA approved for the treatment of adults with short bowel syndrome (SBS) who are dependent on parenteral support. Gattex® works by regeneration of cells in the intestinal lining, improving intestinal absorption of fluids and nutrients, and helping reduce the frequency and volume of parenteral nutrition.
Adapted from IFFGD Publication #258 by: Evelin Eichler, MS, RD, LD, Clinical Dietitian, University Medical Center, Gastrointestinal Motility Nutrition Specialist, Texas Tech University, Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX; Richard McCallum MD, FACP, FRACP (AUST), FACG, Professor of Medicine and Founding Chair and Chief of Gastroenterology, Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX; Susan S. Schneck, MA, International Foundation for Functional Gastrointestinal Disorders, Milwaukee, WI; and William F. Norton, Communications Director, International Foundation for Functional Gastrointestinal Disorders, Milwaukee, WI.